Comparison
Glepaglutide vs. Leuprorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
no data
53714-56-0
Molecular weight
no data
1209.4 g/mol
Half-life
no data
3 h
Sequence
no data
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtMechanism of action
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
4
of which in humans
1
4
Effects recorded
2
4
Open conflicts
0
1
Documented adverse events
1
3
Legal status
Full entries
Frequently asked questions
- What is the difference between Glepaglutide and Leuprorelin?
- Glepaglutide is classified as "Research other", while Leuprorelin is classified as "Research other". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Glepaglutide or Leuprorelin?
- The highest available evidence level is "Human RCT" for Glepaglutide and "Human RCT" for Leuprorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Glepaglutide and Leuprorelin in Germany and the United States?
- Germany: Glepaglutide — Unapproved, Leuprorelin — Prescription. United States: Glepaglutide — Unapproved, Leuprorelin — Prescription. These are factual summaries with source and review date on the individual pages.